Lex Aurum Advisors, LLC Precigen, Inc. Transaction History

Lex Aurum Advisors, LLC

$476 Million
Q4 2024

A detailed history of Lex Aurum Advisors, LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Lex Aurum Advisors, LLC holds 691,544 shares of PGEN stock, worth $1.06 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

691,544

Previous 274,489 151.94%

Holding current value

$1.06 Million

Previous $260,000 197.69%

% of portfolio

0.16%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 21, 2025	BUY	$0.67 - $1.12 $279,426 - $467,101	417,055 Added 151.94%	691,544 $774,000
Q3 2024 Oct 16, 2024	BUY	$0.91 - $1.88 $30,303 - $62,604	33,300 Added 13.81%	274,489 $260,000
Q2 2024 Jul 15, 2024	BUY	$1.27 - $1.75 $193,069 - $266,040	152,023 Added 170.49%	241,189 $381,000
Q1 2024 Apr 10, 2024	SELL	$1.21 - $1.75 $10,406 - $15,050	-8,600 Reduced 8.8%	89,166 $129,000
Q4 2023 Jan 10, 2024	BUY	$0.89 - $1.41 $4,539 - $7,191	5,100 Added 5.5%	97,766 $131,000
Q3 2023 Oct 16, 2023	SELL	$1.08 - $1.85 $10,044 - $17,205	-9,300 Reduced 9.12%	92,666 $131,000
Q2 2023 Jul 25, 2023	SELL	$0.96 - $1.4 $1,920 - $2,800	-2,000 Reduced 1.92%	101,966 $117,000
Q1 2023 Apr 11, 2023	SELL	$0.88 - $2.19 $5,284 - $13,150	-6,005 Reduced 5.46%	103,966 $110,000
Q4 2022 Jan 23, 2023	SELL	$1.27 - $2.26 $49,149 - $87,461	-38,700 Reduced 26.03%	109,971 $0
Q3 2022 Oct 17, 2022	SELL	$1.41 - $2.79 $5,640 - $11,160	-4,000 Reduced 2.62%	148,671 $315,000
Q2 2022 Aug 05, 2022	BUY	$1.15 - $2.53 $4,370 - $9,614	3,800 Added 2.55%	152,671 $205,000
Q1 2022 May 04, 2022	BUY	$1.91 - $3.98 $284,343 - $592,506	148,871 New	148,871 $314,000

Others Institutions Holding PGEN

# of Institutions

140

Shares Held

161M

Call Options Held

232K

Put Options Held

69K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $318M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lex Aurum Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lex Aurum Advisors, LLC with notifications on news.

Account

Lex Aurum Advisors, LLC Precigen, Inc. Transaction History